FLT3 and acute myeloid leukemia: Along with cytotoxic chemotherapy, selection for FLT3-mutated clones is a common resistance mechanism to venetoclax-based therapies which are the current standard-of-care for older or unfit patients with newly-diagnosed AML [20, 21].